On the one hand, circulating anti-SFT2D2 IgG can cross the blood–brain barrier to the brain and lead to targeting of SFT2D2 protein which expresses in the central nervous system, thus contributing to the illness and possibly to schizophrenia pathophysiology. This evidence concerns the gene SFT2D2 and schizophrenia.